The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
A new tool in the tool box?
Facing the next pandemic
NYC school health clinics shutting down as care model evolves
HHS seeks to toss drug pricing suit on IRA anniversary
After Ohio vote, Dems eye Virginia
Bipartisan support grows for psychedelic medicine, but hurdles remain
The undoing of the biggest health care expansion since Obamacare
Pregnancy accommodation rules spark abortion backlash
Behind the drop in the reporting of medical device shortages
Old congressional friends now at odds over Covid
As Medicaid funds dry up, private insurer ups its political contributions
Experts warn of potential fall covid surge as hospitalizations increase
America’s maternity care deserts spread
Congress faces a time crunch to pass critical health bills
Medicaid unwinding may hobble the nation's opioid response
Pending nursing home rules upset both advocates and industry
CDC finds more tuberculous cases linked to bone grafts
Mississippi’s cannabis conundrum: Too much weed, not enough need
Biden cracking down on insurers who skimp on mental health care coverage
GOP readies for spending fight for wins on abortion, trans care
Create your
podcast in
minutes
It is Free